Indirect Pulp Treatment in Primary Teeth

Sponsor
Cairo University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04763057
Collaborator
(none)
88
2
18

Study Details

Study Description

Brief Summary

Conservative approaches such as indirect pulp capping techniques became popular over the last years for the management of deep carious lesions. In particular, indirect pulp-treatment (IPT) techniques have gained remarkable attention in pediatric dentistry, mainly because children require a fast and accurate treatment, besides it enables the affected primary tooth to remain in the mouth until exfoliation without causing any pain or infection.

Condition or Disease Intervention/Treatment Phase
  • Drug: NeoPUTTY MTA
  • Drug: calcium hydroxide
N/A

Detailed Description

Indirect pulp treatment is recommended for teeth with deep caries approximating the pulp with no signs and symptoms of pulp deterioration. In this treatment, the deepest layer of the remaining carious dentine (affected dentin) is covered with biocompatible material followed by an airtight restoration to achieve a good seal against microleakage, without the need to reencounter for the removal of remaining caries.

Calcium hydroxide has served as a gold standard for IPT over the years. However, the introduction of newer bioactive materials such as mineral trioxide aggregate (MTA) and Biodentine helped surpass the demerits of calcium hydroxide such as internal resorption, nonadherence to dentin, degradation over time, tunnel defects, and poor sealing ability.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
88 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Calcium Hydroxide Versus NeoPUTTY MTA in Indirect Pulp Treatment of Primary Molars: A Randomized Clinical Trial
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Oct 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: indirect pulp treatment with NeoPUTTY MTA

Drug: NeoPUTTY MTA
NeoPUTTY, a premixed bioactive bioceramic MTA that triggers hydroxyapatite and supports healing

Active Comparator: indirect pulp treatment with calcium hydroxide

Drug: calcium hydroxide
Calcium hydroxide the gold standard for IPT

Outcome Measures

Primary Outcome Measures

  1. Clinical success in term of the absence of post-operative pain [one year]

    Visual analog scale

  2. Clinical success in term of the absence of pain on percussion, swelling, sinus, or fistula [one year]

    Visual and clinical examinations

Secondary Outcome Measures

  1. Radiographic success in term of the absence of any adverse radiographic findings (eg. internal or external root resorption or other pathologic changes [one year]

    Radiographic examination

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 8 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • • Presence of active carious lesions involving either occlusal or proximal surfaces of primary molars.

  • Extension of carious lesion such that complete caries removal would risk pulp exposure.

  • History of tolerable dull intermittent pain, mild discomfort associated with eating, negative history of spontaneous extreme pain.

  • Radiographically, carious lesion involving more than 2/3rd thickness of dentin approximating the pulp, normal lamina dura, normal periodontal ligament space, more than 2/3rd of root present, no periapical changes, no pathologic external or internal resorption.

Exclusion Criteria:
  • • History of spontaneous sharp, penetrating pain, or tenderness on percussion

  • Presence of tooth mobility, discoloration, sinus opening, or abscessed tooth.

  • Radiographically, presence of interrupted or broken lamina dura, widened periodontal ligament space, periapical radiolucency, internal or external resorption.

  • Pulp exposure during caries removal.

  • Parental refusal for participation.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cairo University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
marwa aly fouad elchaghaby, Lecturer of Pediatric Dentistry and Dental public health, Faculty of Dentistry, Cairo University, Egypt., Cairo University
ClinicalTrials.gov Identifier:
NCT04763057
Other Study ID Numbers:
  • vital pulp treatment
First Posted:
Feb 21, 2021
Last Update Posted:
Feb 21, 2021
Last Verified:
Feb 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 21, 2021